Differentiation of Cord Blood Stem cells into Thymus (T) cells with regulatory phenotype and function

该项目将开发基于脐带血干细胞的干细胞治疗平台技术，以治疗自身免疫性疾病或移植。在阿德莱德大学的脐带血干细胞分化调节性T细胞的前沿示范的基础上，该项目将开发扩大产生的T细胞数量的技术。这有可能保持澳大利亚在脐带血干细胞分化方面的领先地位，并在自身免疫性疾病（例如1型糖尿病）或移植的潜在治疗方面取得重大突破。这些疾病既影响生命的健康开始，也影响健康的老龄化，澳大利亚治疗或治愈这些疾病的发明将产生全球影响。

This project will develop technologies for a stem cell therapy platform based on cord blood stem cells, to enable treatment of autoimmune diseases or transplants. Building on the University of Adelaide's frontier demonstration of differentiation of regulatory Thymus (T) cells from cord blood stem cells, the project will develop techniques to expand the numbers of T cells generated. This has the potential to maintain Australia's lead in differentiation of cord blood stem cells and to provide a significant breakthrough in potential treatments of autoimmune diseases (e.g. type 1 diabetes) or transplantation. These diseases affect both a healthy start to life and healthy ageing, and an Australian invention to treat or cure them would have global impact.